Lethal Prion Protein Causes Neuronal Death
|
By LabMedica International staff writers Posted on 01 Mar 2012 |
A single prion protein that is at least 10 times more lethal than larger prion species has been identified that causes disease similar to mad cow disease.
The toxic form of abnormal prion protein, known as TPrP, triggered various forms of neuronal damage, including molecular signatures very similar to that seen in the brains of prion-infected animal with bovine spongiform encephalopathy (BSE).
Scientists at the Scripps Research Institute (Jupiter, FL, USA) found that the most lethal form of prion protein was a specific structure known as alpha-helical. This toxic single molecule or "monomer" tests the existing theory that neuronal damage is associated with the toxicity of prion protein aggregates called "oligomers."
A variety of techniques was used to provide fresh insights into prion diseases, such as BSE and a rare human form Creutzfeldt-Jakob disease. Furthermore, it opened the possibility that associated neurotoxic proteins may play a role in neurodegenerative disorders, such as Parkinson, and Alzheimer's diseases.
In prion disease, proteinaceous infectious particles (infectious prions), believed to be made up only of protein, are able to reproduce, even though they lack ribonucleic acid (RNA) and DNA. Usually, mammalian cells generate cellular prion protein (PrP), when infected with a prion disease; the abnormal protein converts the normal host prion protein into its disease form.
Corinne Lasmézas, PhD, the lead author and a professor at Scripps, said "By identifying a single molecule as the most toxic species of prion proteins, we've opened a new chapter in understanding how prion-induced neurodegeneration occurs. We didn't think we would find neuronal death from this toxic monomer so close to what normally happens in the disease state. Now we have a powerful tool to explore the mechanisms of neurodegeneration."
Professor Lasmézas added, "Until now, it was thought that oligomers of proteins are toxic in all these disease. Since we found for the first time that an abnormally folded monomer is highly toxic, it opens up the possibility that this might be true also for some other protein misfolding diseases as well." The study was published on February 7, 2012 in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Scripps Research Institute
The toxic form of abnormal prion protein, known as TPrP, triggered various forms of neuronal damage, including molecular signatures very similar to that seen in the brains of prion-infected animal with bovine spongiform encephalopathy (BSE).
Scientists at the Scripps Research Institute (Jupiter, FL, USA) found that the most lethal form of prion protein was a specific structure known as alpha-helical. This toxic single molecule or "monomer" tests the existing theory that neuronal damage is associated with the toxicity of prion protein aggregates called "oligomers."
A variety of techniques was used to provide fresh insights into prion diseases, such as BSE and a rare human form Creutzfeldt-Jakob disease. Furthermore, it opened the possibility that associated neurotoxic proteins may play a role in neurodegenerative disorders, such as Parkinson, and Alzheimer's diseases.
In prion disease, proteinaceous infectious particles (infectious prions), believed to be made up only of protein, are able to reproduce, even though they lack ribonucleic acid (RNA) and DNA. Usually, mammalian cells generate cellular prion protein (PrP), when infected with a prion disease; the abnormal protein converts the normal host prion protein into its disease form.
Corinne Lasmézas, PhD, the lead author and a professor at Scripps, said "By identifying a single molecule as the most toxic species of prion proteins, we've opened a new chapter in understanding how prion-induced neurodegeneration occurs. We didn't think we would find neuronal death from this toxic monomer so close to what normally happens in the disease state. Now we have a powerful tool to explore the mechanisms of neurodegeneration."
Professor Lasmézas added, "Until now, it was thought that oligomers of proteins are toxic in all these disease. Since we found for the first time that an abnormally folded monomer is highly toxic, it opens up the possibility that this might be true also for some other protein misfolding diseases as well." The study was published on February 7, 2012 in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Scripps Research Institute
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








